Perjeta is the brand name for pertuzumab, a humanized monoclonal antibody used in HER2-positive breast cancer treatment. It is commonly used in combination with trastuzumab and chemotherapy in metastatic and early-stage settings. The FDA first approved Perjeta on June 8, 2012.
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
Former Novartis executive John Tsai has been appointed global head of R&D at Daiichi Sankyo, replacing Ken Takeshita effective April 1. Tsai brings over 25 years of leadership experience in drug development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06884254 |
Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. |
WITHDRAWN | PHASE3 |
| NCT05802225 |
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05738993 |
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers |
UNKNOWN | PHASE1 |
| NCT05323981 |
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection |
COMPLETED | PHASE1 |
| NCT03161353 |
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03058939 |
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer |
WITHDRAWN | PHASE2 |
